Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 9, Issue 1, Pages 69-79
Publisher
Informa UK Limited
Online
2015-11-05
DOI
10.1586/17512433.2016.1102052
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thyroid Carcinoma, Version 2.2014
- (2017) R. Michael Tuttle et al. Journal of the National Comprehensive Cancer Network
- Osteonecrosis of the jaw in a patient receiving cabozantinib
- (2015) R Marino et al. AUSTRALIAN DENTAL JOURNAL
- Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis
- (2015) V. R. Belum et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis
- (2015) Dale Miles et al. CLINICAL PHARMACOKINETICS
- Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
- (2015) Rashmi R. Shah et al. DRUG SAFETY
- THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis
- (2015) E. N. Klein Hesselink et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Sorafenib for the treatment of thyroid cancer: an updated review
- (2015) Jolanta Krajewska et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials
- (2014) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
- (2014) Sariah Liu et al. CANCER TREATMENT REVIEWS
- Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer
- (2014) Sheridan M. Hoy DRUGS
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
- (2014) Frédéric Illouz et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network
- (2014) Marie-Hélène Massicotte et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
- (2014) Keith C. Bible et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
- (2014) Ze-Feng Zhang et al. PLoS One
- Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma
- (2014) Sahzene Yavuz et al. THYROID
- Overview and Management of Dermatologic Events Associated with Targeted Therapies for Medullary Thyroid Cancer
- (2014) Mario E. Lacouture et al. THYROID
- 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
- (2013) Giuseppe Mancia et al. BLOOD PRESSURE
- Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
- (2013) E. Fox et al. CLINICAL CANCER RESEARCH
- Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma
- (2013) Cristina Rodríguez-Antona et al. ENDOCRINE-RELATED CANCER
- Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis
- (2013) Rafael Selbach Scheffel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Tyrosine Kinase Inhibitor–Induced Thyroid Disorders: A Review and Hypothesis
- (2013) Noriko Makita et al. THYROID
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer
- (2013) Dean P. Blevins et al. THYROID
- Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
- (2013) Serena Giunti et al. International Journal of Endocrinology
- Mechanisms of TKI-induced diarrhea in cancer patients
- (2013) Joanne M. Bowen Current Opinion in Supportive and Palliative Care
- Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
- (2012) Sandra Feldt et al. EUROPEAN JOURNAL OF CANCER
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
- (2012) Fabio A.B. Schutz et al. JOURNAL OF CLINICAL ONCOLOGY
- How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals
- (2012) Ka Kit Wong et al. NUCLEAR MEDICINE COMMUNICATIONS
- Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
- (2012) Jiajie Zang et al. PLoS One
- Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
- (2011) Doreen Braun et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Medullary Thyroid Carcinoma: Time to Focus the Spotlight on This Rare Disease
- (2011) Yariv Houvras et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer
- (2011) Marie-Elisabeth Toubert et al. THYROID
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- Dual PET/CT with 18F-DOPA and 18F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging
- (2010) M.C. Marzola et al. EJSO
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU
- (2010) A. Ravaud et al. ONCOLOGIST
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
- (2009) M M Moura et al. BRITISH JOURNAL OF CANCER
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
- (2009) Richard T. Kloos (Chair) et al. THYROID
- Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
- (2008) Frédéric Illouz et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas
- (2008) S. Dvorakova et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More